Holen Sie sich die Stockscreener-App
53.60
1.63%
0.86
Handel nachbörslich:
53.60
Crinetics Pharmaceuticals Inc Aktie (CRNX) Neueste Nachrichten
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Bought by Geode Capital Management LLC - MarketBeat
Crinetics Pharmaceuticals' SWOT analysis: promising pipeline drives stock outlook - Investing.com
(CRNX) Trading Advice - Stock Traders Daily
Crinetics Pharmaceuticals (NASDAQ:CRNX) Given Market Outperform Rating at JMP Securities - Defense World
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Acquired by Franklin Resources Inc. - MarketBeat
Barclays PLC Acquires 89,358 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
Crinetics Pharmaceuticals names new Chief Commercial Officer By Investing.com - Investing.com Canada
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Short Interest Update - MarketBeat
Crinetics Pharmaceuticals names new Chief Commercial Officer - Investing.com India
Acromegaly Pipeline Trends 2024: Clinical Trials, Therapeutic - openPR
Isabel Kalofonos Joins Crinetics Pharmaceuticals as Chief Commercial Officer - citybiz
Crinetics appoints Isabel Kalofonos as CCO - TipRanks
JMP Securities Reaffirms Market Outperform Rating for Crinetics Pharmaceuticals (NASDAQ:CRNX) - MarketBeat
Neurocrine's Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potential - Benzinga
Crinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer - The Manila Times
Crinetics Pharma Strengthens Commercial Leadership, Names Veteran Launch Expert as Chief Commercial Officer - StockTitan
Crinetics Pharmaceuticals' SWOT analysis: promising pipeline drives stock outlook By Investing.com - Investing.com Australia
Lord Abbett & CO. LLC Decreases Stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
State Street Corp Purchases 25,561 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
BNP Paribas Financial Markets Boosts Stock Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
Crinetics Pharmaceuticals Announces December 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Crinetics Pharmaceuticals Awards Stock Options to New Talent in Strategic Expansion Move - StockTitan
Crinetics Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly - Marketscreener.com
Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly - The Manila Times
Crinetics' Breakthrough Oral Acromegaly Drug Advances as FDA Accepts NDA for First-in-Class Treatment - StockTitan
Wellington Management Group LLP Sells 160,722 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives $70.18 Average Target Price from Analysts - MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
73,340 Shares in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Bought by Castleark Management LLC - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $13.89 Million Stock Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
Certain Stock Option of Crinetics Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 8-DEC-2024. - Marketscreener.com
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Sold by Janus Henderson Group PLC - MarketBeat
Parkman Healthcare Partners LLC Sells 63,752 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Stock Holdings Raised by Charles Schwab Investment Management Inc. - MarketBeat
Cinctive Capital Management LP Makes New Investment in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Bought by Fmr LLC - MarketBeat
Martingale Asset Management L P Purchases New Stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
Crinetics Pharmaceuticals (FRA:6Z4) EPS (Diluted) : €-3.42 (TTM As of Sep. 2024) - GuruFocus.com
Vestal Point Capital LP Makes New $10.48 Million Investment in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
Intech Investment Management LLC Purchases New Shares in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
Fisher Asset Management LLC Acquires 37,429 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
Congenital Hyperinsulinism Pipeline 2024: Clinical Trials - openPR
Natixis Advisors LLC Purchases 11,870 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Lowers Stock Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
Principal Financial Group Inc. Acquires 64,504 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
Crinetics Pharmaceuticals' SWOT analysis: biotech stock poised for growth with rich pipeline - Investing.com
Jennison Associates LLC Acquires 13,470 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
Victory Capital Management Inc. Has $17.55 Million Stock Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
First Turn Management LLC Cuts Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
Leerink Partnrs Issues Optimistic Forecast for CRNX Earnings - MarketBeat
Learn to Evaluate (CRNX) using the Charts - Stock Traders Daily
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):